Richard de Boer

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Ian E. Krop, Ingrid A. Mayer, Vinod Ganju et al. · The Lancet Oncology · 2016 · 295 citations

Medicine, Oncology, Pharmacology +12

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

Ian E. Krop, Stephen Johnston, Ingrid A. Mayer et al. · Cancer Research · 2015 · 60 citations

Medicine, Oncology, Pharmacology +17

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Adam Platt, John Morten, Qunsheng Ji et al. · BMC Cancer · 2015 · 59 citations · Full text

Medicine, Genetics, Oncology +17

Differences of Opinion

Ross Jennens, Richard de Boer, Louis Irving et al. · CHEST Journal · 2004 · 58 citations

Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer

Vanessa Wong, Richard de Boer, Sally Baron‐Hay et al. · Clinical Breast Cancer · 2022 · 15 citations

Medicine, Oncology, Pharmacology +17